Misplaced Pages

:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Edrecolomab: Difference between pages - Misplaced Pages

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Difference between pages)
Page 1
Page 2
Content deleted Content addedVisualWikitext
Revision as of 10:54, 17 November 2011 editBeetstra (talk | contribs)Edit filter managers, Administrators172,074 edits Saving copy of the {{drugbox}} taken from revid 456518685 of page Edrecolomab for the Chem/Drugbox validation project (updated: 'CAS_number').  Latest revision as of 20:33, 1 December 2023 edit Buidhe (talk | contribs)Autopatrolled, Extended confirmed users, Page movers, File movers, Mass message senders, New page reviewers, Pending changes reviewers, Template editors136,147 editsm Moving from Category:Experimental drugs to Category:Experimental monoclonal antibodies using Cat-a-lot 
Line 1: Line 1:
{{Short description|Monoclonal antibody}}
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid of page ] with values updated to verified values.}}
{{Drugbox {{Drugbox
| Verifiedfields = changed | Verifiedfields = changed
| verifiedrevid = 447617838 | verifiedrevid = 461092781
| image = | image =
<!-- Monoclonal antibody data -->

<!--Monoclonal antibody data-->
| type = mab | type = mab
| mab_type = mab | mab_type = mab
| source = o | source = o
| target = ] (17-1A) | target = ] (17-1A)
<!-- Clinical data -->

| tradename = Panorex
<!--Clinical data-->
| tradename =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X --> | pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category = | pregnancy_category =
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> | legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII --> | legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C --> | legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> | legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = | legal_status =
| routes_of_administration = | routes_of_administration =
<!-- Pharmacokinetic data -->

| bioavailability =
<!--Pharmacokinetic data-->
| bioavailability = | protein_bound =
| protein_bound = | metabolism =
| elimination_half-life =
| metabolism =
| excretion =
| elimination_half-life =
<!-- Identifiers -->
| excretion =

<!--Identifiers-->
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = NA | ChemSpiderID = none
| CAS_number_Ref = {{cascite|correct|??}} | CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = <!-- blanked - oldvalue: 156586-89-9 --> | CAS_number = 156586-89-9
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 0KYI9U9FSJ
| ATC_prefix = L01 | ATC_prefix = L01
| ATC_suffix = XC01 | ATC_suffix = FX01
| PubChem = | PubChem =
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = | DrugBank = DB13375
<!-- Chemical data -->
| chemical_formula =
| molecular_weight =
}}


'''Edrecolomab''' (MAb17-1A, trade name '''Panorex''') is a mouse-derived ] targeting the cell-surface ] ] (17-1A), which is expressed on ] and on various ]s.
<!--Chemical data-->
| chemical_formula =


Preliminary studies had shown promise of a possible use in patients with stage III ] (with ] to the ]).<ref name="Lancet1994">{{cite journal | vauthors = Riethmüller G, Schneider-Gädicke E, Schlimok G, Schmiegel W, Raab R, Höffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R | display-authors = 6 | title = Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group | journal = Lancet | volume = 343 | issue = 8907 | pages = 1177–83 | date = May 1994 | pmid = 7909866 | doi = 10.1016/s0140-6736(94)92398-1 | s2cid = 45574458 }}</ref><ref name="Proc2002">{{cite journal | vauthors = Punt CJ, Nagy A, Douillard JY, Figer A, Skovsgaard T, Monson J, Barone C, Fountzilas G, Riess H, Moylan E, Jones D, Dethling J, Colman J, Coward L, MacGregor S | display-authors = 6 | title = Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study | journal = Lancet | volume = 360 | issue = 9334 | pages = 671–7 | date = August 2002 | pmid = 12241873 | doi = 10.1016/S0140-6736(02)09836-7 | s2cid = 42391189 }}</ref> No effect has been demonstrated for stage II (locally advanced cancer without spread to the lymph nodes) colon cancer.<ref name="stageII">{{cite journal | vauthors = Colacchio TA, Niedzwiecki D, Compton C, Warren R, Benson AI, Goldberg R, Kerr D, Fields A, Hollis D, Mayer R | title = Phase III trial of adjuvant immunotherapy with MOAb 17–1A following resection for stage II adenocarcinoma of the colon (CALGB 9581) | journal = Journal of Clinical Oncology | date = July 2004 | volume = 22 | issue = 14_suppl | pages = 3522 | doi = 10.1200/jco.2004.22.90140.3522 }}</ref>
| molecular_weight =

}}
Edrecolomab was well tolerated in these studies and as such research has now concentrated on whether it can be of any use in other forms of cancer.

== References ==
{{reflist|2}}

{{Extracellular chemotherapeutic agents}}
{{Monoclonals for tumors}}

]
]
{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}
Misplaced Pages:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Edrecolomab: Difference between pages Add topic